Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by I Judson
Clinical Benefit in Phase-I Trials of Novel Molecularly Targeted Agents: Does Dose Matter?
British Journal of Cancer
Cancer Research
Oncology
Continuous-Infusion Verapamil With Etoposide in Relapsed or Resistant Paediatric Cancers
British Journal of Cancer
Cancer Research
Oncology
Related publications
Delayed Adverse Events in Phase I Trials of Molecularly Targeted and Cytotoxic Agents
Oncotarget
Oncology
A Bayesian Dose Finding Design for Clinical Trials Combining a Cytotoxic Agent With a Molecularly Targeted Agent
Journal of the Royal Statistical Society. Series C: Applied Statistics
Uncertainty
Statistics
Probability
A Dose-Schedule Finding Design for Phase I-Ii Clinical Trials
Journal of the Royal Statistical Society. Series C: Applied Statistics
Uncertainty
Statistics
Probability
Phase I Cancer Clinical Trials
British Journal of Cancer
Cancer Research
Oncology
Choice of Starting Dose for Biopharmaceuticals in First-In-Human Phase I Cancer Clinical Trials
Oncologist
Cancer Research
Medicine
Oncology
Determinants of the Recommended Phase 2 Dose of Molecular Targeted Agents
Cancer
Cancer Research
Oncology
Validation of Prognostic Scoring and Assessment of Clinical Benefit for Patients With Bone Sarcomas Enrolled in Phase I Clinical Trials
Oncotarget
Oncology
Clinical Benefit of Patients With Advanced Adrenocortical Carcinoma (Acc) Treated in Phase I Clinical Trials: The Royal Marsden Hospital (Rmh) Experience
Endocrine Abstracts
Feasibility and Benefit of Molecularly-Informed Enrollment Into Early Phase Clinical Trials for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
